c-Met receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
=== Aging and obesity === NF-κB is increasingly expressed with obesity and aging, resulting in reduced levels of the anti-inflammatory, pro-autophagy, anti-insulin resistance protein sirtuin 1. NF-κB increases the levels of the microRNA miR-34a, which inhibits nicotinamide adenine dinucleotide (NAD) synthesis by binding to its promoter region, resulting in lower levels of sirtuin 1. NF-κB and interleukin 1 alpha mutually induce each other in senescent cells in a positive feedback loop causing the production of senescence-associated secretory phenotype (SASP) factors. NF-κB and the NAD-degrading enzyme CD38 also mutually induce each other. NF-κB is a central component of the cellular response to damage. NF-κB is activated in a variety of cell types that undergo normal or accelerated aging. Genetic or pharmacologic inhibition of NF-κB activation can delay the onset of numerous aging related symptoms and pathologies. This effect may be explained, in part, by the finding that reduction of NF-κB reduces the production of mitochondria-derived reactive oxygen species that can damage DNA.
The vast majority of genetically modified animals are at the research stage with the number close to entering the market remaining small. As of 2018 only three genetically modified animals have been approved, all in the USA. A goat and a chicken have been engineered to produce medicines and a salmon to increase its growth. Despite the differences and difficulties in modifying them, the end aims are much the same as for plants. GM animals are created for research purposes, production of industrial or therapeutic products, agricultural uses, or improving their health. There is also a market for creating genetically modified pets.
== Phylogenetics of cytochrome c == Cytochrome c is a highly conserved protein across the spectrum of eukaryotic species, found in plants, animals, fungi, and many unicellular organisms. This, along with its small size (molecular weight about 12,000 daltons), makes it useful in studies of cladistics. Cytochrome c has been studied for the glimpse it gives into evolutionary biology. Cytochrome c has a primary structure consisting of a chain of about 100 amino acids. Many higher-order organisms possess a chain of 104 amino acids. The sequence of cytochrome c in humans is identical to that of chimpanzees (our closest relatives), but differs from that of horses. Cytochrome c has an amino acid sequence that is highly conserved in eukaryotes, varying by only a few residues. In more than thirty species tested in one study, 34 of the 104 amino acids were conserved (identical at their characteristic position). For example, human cytochrome oxidase reacted with wheat cytochrome c, in vitro; which held true for all pairs of species tested. In addition, the redox potential of +0.25 volts is the same in all cytochrome c molecules studied.
Sources: en.wikipedia.org
Ovaleap was approved for medical use in the European Union in September 2013. It was approved for medical use in Australia in March 2021. Bemfola was approved for medical use in the European Union in March 2014.
In his work with the late Hans Eysenck and subsequently with Con Stough on the role of basic information processing speed in human intelligence, he used ERP complexity measures to argue for a modification to the Hendrickson and Hendrickson error or "string theory" (so named as pins and string were used to make the measurements of EEG output) model of ability, to include a controlling role of attention. In related work on reaction time, he introduced a novel modification to the Jensen box, again controlling the role of attention in this task, and suggesting that under these conditions, intelligence is, as Arthur Jensen proposed, related to the rate of information processing defined in Fitts Law and using Claude Shannon's information metrics. At the University of Edinburgh he has investigated individual differences in intelligence, memory, and the genetic and environmental influences on social behaviours, such as coalition affiliation, politics, and altruism. Working with Ian Deary, Paul Irwing, and Geoff Derr, he reported evidence for substantial gender differences in intelligence in the form of much larger variance amongst males than amongst females, with more boys and men scoring in both the extreme high range, and in the extreme low range.
7 and Transitional Provisions) Order 1993 (S.I. 1993/2229) National Assistance (Assessment of Resources) (Amendment No.2) Regulations 1993 (S.I. 1993/2230) National Curriculum Council and School Examinations and Assessment Council (Designation of Staff) Order 1993 (S.I. 1993/2231) Export of Goods (Control) (Haiti) (Revocation) Order 1993 (S.I. 1993/2232) Motor Vehicles (Competitions and Trials) (Amendment) Regulations 1993 (S.I. 1993/2233) Road Traffic (Special Parking Areas) (London Boroughs of Bromley, Hammersmith and Fulham and Lewisham) (London Borough of Wandsworth) (Amendment) Order 1993 (S.I. 1993/2237) Housing (Extension of Right to Buy) Order 1993 (S.I. 1993/2240) Housing (Preservation of Right to Buy) Regulations 1993 (S.I. 1993/2241) Valuation Timetable (Scotland) Amendment (No.3) Order 1993 (S.I. 1993/2242) Housing (Right to Buy Delay Procedure) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2245) Housing (Right to Buy) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2246) Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (Commencement No.12) Order 1993 (S.I. 1993/2253) Public Trusts (Reorganisation) (Scotland) (No.2) Regulations 1993 (S.I. 1993/2254) Fish Health (Amendment) Regulations 1993 (S.I. 1993/2255) Royal National Hospital for Rheumatic Diseases National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2256) St Peter's Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
==== Pancreatic cancer ==== First-in-human application of different αvβ6-integrin radiotracers has demonstrated that 68Ga-Trivehexin performed especially well in detecting pancreatic cancer, showing high uptake in tumor lesions and low background in the gastrointestinal tract (GI tract) (see image). Since its introduction, 68Ga-Trivehexin has been used predominantly for PET/CT imaging of pancreatic ductal adenocarcinoma (PDAC), for example, in single cases and two cohorts (12 and 44 patients, respectively) of suspected or known PDAC.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.